43
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Epidemiology and Health Impacts of Neuroendocrine Tumors

      Submit here before August 30, 2024

      About Neuroendocrinology: 3.2 Impact Factor I 8.3 CiteScore I 1.009 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Altered Bone Mineral Density in Patients with Complete Androgen Insensitivity Syndrome

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Androgens have major influences on the regulation of bone mineralization. Because of their unique peripheral metabolism androgens may act on bone via activation of the androgen and/or estrogen receptor. Patients with complete androgen insensitivity syndrome (cAIS) are natural models to assess androgen actions on bone. We studied bone mineral density (BMD) in 10 patients with cAIS (mean age 13.70, range 4.7–19.8 years); 3 patients were studied before gonadectomy; the others were castrated and 6 were on hormonal replacement therapy. The BMD area (aBMD) was measured by dual energy X-ray; lumbar ‘apparent’ volumetric density (vBMD) was calculated using the formula vBMD = aBMD × [4/(π × width)]. In the patients, aBMD (0.72 ± 0.16 g/cm<sup>2</sup>) and vBMD (0.23 ± 0.04 g/cm<sup>3</sup>) were significantly (p < 0.001) reduced in comparison with those of a control group (n = 15, age 5.0–20.5 years: aBMD 1.028 ± 0.20 g/cm<sup>2</sup>; vBMD 0.35 ± 0.04 g/cm<sup>3</sup>). Both aBMD and vBMD were also reduced in comparison with normal values for males (aBMD –2.66 ± 0.99 SDS, p < 0.001; vBMD –3.08 ± 1.53 SDS, p < 0.0005) and females (aBMD –2.88 ± 1.05 SDS, p < 0.001; vBMD –2.84 ± 1.18 SDS, p < 0.0007). Real lumbar bone density, assessed by computed tomography in 1 patient, was also reduced (–6.2 SDS and –3.5 SDS for male and female normal values, respectively). Biochemical markers of bone metabolism were normal and not significantly different in patients and controls. Girls with cAIS did not have more fractures than controls. In conclusion, both aBMD and vBMD are reduced in cAIS patients, while bone turnover and the fracture risk seem not to be increased. Our data indicate that both androgens and estrogens may be required for acquisition of bone density during childhood.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: not found
          • Article: not found

          Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Androgen receptor defects: historical, clinical, and molecular perspectives [published erratum appears in Endocr Rev 1995 Aug;16(4):546]

            C Quigley (1995)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Androgen-receptor blockade does not impair bone mineral density in adolescent females.

              The effect of peripheral androgen hypersensitivity on bone mineral density (BMD) was investigated in a group of adolescent women with idiopathic hirsutism (n = 17; mean age 17.0 +/- 1.7 years). The effect of long-term androgen-receptor blockade with flutamide (500 mg daily in two divided doses for 12 months) on BMD was assessed too. BMD was measured at lumbar spine (L2-L4) by a dual energy X-ray densitometer. Before flutamide treatment, patient BMD (1.14 +/- 0.07 g/cm2) was not significantly different from that of the control group (1.16 +/- 0.12 g/cm2, n = 22), and was normal for age and sex (BMD 0.14 +/- 0.69 SDS, P = NS vs. 0). After 12 months of treatment, absolute BMD in patients increased (1.18 +/- 0.08 g/cm2, P < 0.002), but SDS BMD did not change (0.21 +/- 0.72, P = NS vs. baseline). Flutamide treatment determined a clinical, marked improvement of androgen hypersensitivity (Ferriman-Gallwey score: before 22.0 +/- 6.2; 6 months: 13.2 +/- 6.4, P < 0.003; 12 months; 7.6 +/- 4.1, P < 0. 001; acne score: before 3.8 +/- 0.8; 3 months 0.8 +/- 0.5, P < 0. 001; later disappeared). The serum levels of 3alpha-androstenediol-glucoronide decreased (before: 8.6 +/- 1.1 microg/liter; 12 months: 7.2 +/- 1.0 microg/liter, P < 0.02), whereas the other endocrinological parameters did not change. No relationship was found between BMD and clinical or biochemical parameters of hyperandrogenism. We concluded that in adolescent women, peripheral hyperandrogenism is not associated with abnormal BMD; long-term treatment with flutamide, which blocks the androgen receptor, does not alter their BMD.
                Bookmark

                Author and article information

                Journal
                HRE
                Horm Res Paediatr
                10.1159/issn.1663-2818
                Hormone Research in Paediatrics
                S. Karger AG
                1663-2818
                1663-2826
                1998
                December 1998
                12 February 1999
                : 50
                : 6
                : 309-314
                Affiliations
                a Pediatric Endocrine Unit, Department of Reproductive Medicine and Pediatrics, University of Pisa, ‘Santa Chiara’ Hospital, Pisa; b Pediatric Hospital ‘Bambino Gesù’, Rome and c Pediatric Endocrine Division, Pediatric Hospital ‘Regina Margherita’, Turin, Italy
                Article
                23296 Horm Res 1998;50:309–314
                10.1159/000023296
                9973670
                69335d00-17a0-47dc-84fb-681b5d001b91
                © 1998 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Page count
                Figures: 2, Tables: 1, References: 37, Pages: 6
                Categories
                Original Paper

                Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
                Bone markers,Dual energy X-ray absorptiometry,Androgen receptor,Bone mineral density,Complete androgen insensitivity syndrome

                Comments

                Comment on this article